Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Q: The Utah Senate and House of Representatives voted unanimously Monday evening during a special session to send the proposal to Republican Gov. Gary Herbert's desk. The measure would replace plans for an unusual state-run dispensary system with 14 privately run pharmacies and adopt protections for patients who are concerned they could be prosecuted for drug crimes, among other changes. Utah backtracked from the state-run dispensary after county attorneys expressed concern that such a system would put public employees at risk of being prosecuted under federal drug laws. Republican Senate Majority Leader Evan Vickers, who drafted the law, said his team is "doing everything we can" to improve patient access and have product ready by next March. Some lawmakers said they still have heartburn over certain aspects of the bill, sharing reservations about product distribution and a looming fear of federal prosecution. Democratic Sen. Derek Kitchen said he's concerned patients in rural parts of the state may have to pay more to access marijuana. Before the House vote, Republican Rep. Keven Stratton suggested Utah seek a federal waiver to protect the state program from prosecution under federal drug laws. Marijuana is banned at the federal level, though a congressional amendment blocks the Justice Department from interfering with states' medical marijuana programs. The measure dictated that the courts may not treat a medical marijuana patient differently than someone who uses any other prescribed, controlled substance. Another change prohibited the state from issuing cultivation and pharmacy licenses to legislators. "A lot of money flows through this industry, some back to legislators," Vickers said. "We don't want legislators to have undue influence in an industry they want to have ownership in." Debates in the chamber reflected ongoing tensions over amendments regarding distribution and prosecution of drug crimes. During a tense public hearing last week, members of the conservative group Utah Eagle Forum lamented the loss of the state-run dispensary system, while some medical marijuana advocates raised concern that there wouldn't be enough private dispensaries to meet growing patient demand. An earlier version of the law imagined 12 privately run dispensaries instead of the state-run system. In the same meeting, a proposal outlining patient protections caused an emotional back-and-forth between conservative attorneys who argued parents couldn't take care of children while using marijuana and patients who said the drug makes them better caretakers and helps them manage their pain. Utah residents voted to legalize medical marijuana via ballot measure in November. The revised law became effective in December after a compromise that secured the support of The Church of Jesus Christ of Latter-day Saints and some marijuana advocates. However, the deal drew backlash from other advocates as it banned many marijuana edibles, placed additional restrictions on growing cannabis and made fewer medical conditions eligible for treatment with pot. Other changes addressed issues with land ordinances for cultivation facilities and marijuana research at in-state universities. Marijuana advocates said they are optimistic about the changes adopted. "There's a light at the end of the tunnel, we see legislators working together, and they're willing to work out a plan for patients," Desiree Hennessy, director of the Utah Patients Coalition, said. Republican Rep. Brad Daw acknowledged the measure as a good first step but expects additional changes to the program in January. "I have close friends who, for them, cannabis is the only option, it relieves the kind of pain they have ... we have every right and responsibility to work toward a law that allows medical cannabis to patients who need it," he said. "Is this bill perfect? Of course not. Is this done? No, it's not."

A: Utah lawmakers approve changes to medical cannabis law.
****
Q: Scientists said on Wednesday many Tibetans possess a rare variant of a gene involved in carrying oxygen in the blood that they likely inherited from an enigmatic group of extinct humans who interbred with our species tens of thousands of years ago. It enables Tibetans to function well in low oxygen levels at elevations upwards of 15,000 feet (4,500 meters) like the vast high plateau of southwestern China. People without this variant would be apt to develop thick blood, leading to high blood pressure, heart attacks, strokes, low-birth-weight babies and higher infant mortality. This version of the EPAS1 gene is nearly identical to one found in Denisovans, a lineage related to Neanderthals - but is very different from other people today. Denisovans are known from a single finger bone and two teeth found in a Siberian cave. DNA testing on the 41,000-year-old bone indicated Denisovans were distinct from our species and Neanderthals. "Our finding may suggest that the exchange of genes through mating with extinct species may be more important in human evolution than previously thought," said Rasmus Nielsen, a computational biology professor at the University of California, Berkeley and the University of Copenhagen, whose study appears in the journal Nature. Our genome contains residual genetic fragments from other organisms like viruses as well as species like Neanderthals with which early modern humans interbred. The researchers called their study the first to show that a gene from an archaic human species has helped modern humans adjust to different living conditions. "Such exchange of genes with other species may in fact have helped humans adapt to new environments encountered as they spread out of Africa and into the rest of the world," said Nielsen. Asan Ciren, a researcher with China's BGI genomics center, added, "The genetic relationship or blood relationship between modern humans and archaic hominins is a hot topic of the current paleoanthropology." The researchers said early modern humans trekking out of Africa interbred with Denisovans in Eurasia en route to China. Their descendants harbor a tiny percentage of Denisovan DNA. Genetic studies show nearly 90 percent of Tibetans have the high-altitude gene variant, along with a small percentage of Han Chinese, who share a common ancestor with Tibetans. It is seen in no other people. The researchers conducted genetic studies on 40 Tibetans and 40 Han Chinese and performed a statistical analysis showing that the gene variant almost certainly was inherited from the Denisovans. The gene regulates production of hemoglobin, a protein in red blood cells that carries oxygen. It is turned on when blood oxygen levels drop, stimulating more hemoglobin production. At elevations above 13,000 feet (4,000 meters), the common form of the gene boosts hemoglobin and red blood cell production, causing dangerous side effects. The Tibetans' variant increases hemoglobin and red blood cell levels only modestly, sparing them these effects.

A: Gene from extinct human species fortifies high-altitude Tibetans.
****
Q: The story mentioned that it was expected that the drug reported on would cost $8/day as compared with <$1/day for warfarin. One aspect of costs that were not considered in this story is the difference in monitoring, which would be less with patients using Eliquis. The competing HealthDay story did a better job on this latter point. The story provided only relative risk reduction figures "prevented 21 percent more strokes31 percent fewer incidents of major bleedingreduced total deaths by 11 percent" but neglected to present the absolute decrease in adverse events. 21% of what? 31% of what? 11% of what? The story mentioned some of the disadvantages associated with this use of the medication reported on. It did not specifically detail whether there were any harms associated with this medication or how well people in the study were able to stick with the dosing schedule. On this issue, this story was not as complete as its HealthDay competition, which reported: "The new trial comes on the heels of another study on apixaban that was stopped early due to safety concerns. In that trial, published in July in the New England Journal of Medicine, apixaban's use was associated with raised odds for bleeding without providing patients with any reduction in heart attack risk.However, "in that case, apixaban was given to patients with coronary artery disease who were also taking two other blood thinners," Ansell noted. "The three of them together showed that the risk of bleeding was just too high and there was no real benefit in that population. But, that's an entirely different problem, compared with atrial fibrillation," he said." The story included a lot of information about the study it reported on where the results were presented and published, its design, the number of clinical sites, countries involved, the number of people studied and the length of time they were studied.. No overt disease mongering. The story mentioned that the study reported on had been funded by the drug maker. It included comments from a clinician who had no ties to the study reported on. The story compared the study drug with the long time treatment, warfarin, as well as mentioning a newly approved medication and another medication in the approval process. The story opened by indicating that Eliquis (apixabane) was experimental and closed by indicating the expectation of submission to the FDA for approval. The story was clear that this was a new medication, though there are two other medications (warfarin and Pradax) that are currently available. Did not appear to rely solely on a news release.

A:
Trial Shows Blockbuster Potential for Blood Clot Pill
****